Framework Journal · one stock, one dated entry

Recorded 2025-06-30 · Permanent

InMed Pharmaceuticals Inc INM

Outside both standards

An entry written while the outcome is still unknown. It will be scored by what the market does next, and it will never be edited to look cleverer than it was.

In plain words · InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States.

The label
Markdown

read at $1.52

InMed Pharmaceuticals Inc holds its Markdown at $1.52.

PHINPOOPSC
  • PHPhase · the trend structure carries the Markdown label
  • INInsiders · no filings inside 60 days, left as found
  • POPositioning · no disclosures inside 60 days, left as found
  • OPOptions · no verdict drawn today, left as found
  • SCScreen · does not pass the values gate
  • edge confirmed
  • edge broken
  • edge forming

Each arm is one independent read. Conviction is not a single call, it is how many edges converge.

The investor read · the season, not the day

As held on the ledger · 2025-06-30
PhaseMarkdown · caution
Quantitative stateElevated stress, defensive posture warranted, held for 11 days
Price$1.52
ValuationN/A trailing · -0.24 forward price to earnings
Values screenFAIL · score 70.0
Beta0.96

The business, in plain words · what the numbers mean

The fundamentals · plain-English read
Forward P/E-0.2x
Profit margin-172.2%
currently unprofitable
Return on equity-112.6%
not currently earning a positive return on equity
Debt to equity0.06
minimal debt — a conservative balance sheet
Current ratio3.12
comfortably covers its short-term bills
Beta0.96
steadier than the market
Market cap$8M
Employees13

The risks · The things to watch: it's a small-cap, so the share price can swing harder than the market; its business and earnings are exposed to Canada and to currency swings; as a drug manufacturers - specialty & generic name, trial and regulatory outcomes can move it sharply either way.

Plain-English interpretation of our own screen data. Analysis, not advice.

Related securities · others in INM's space worth a look

Screened names in the same industry · explore each on its own page.

The trader read · the latest dated commentary

The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 47%. Our forward projection puts the odds of a 10% gain over the next month near 27%. Entered 2026-08-02 · Accumulation

The dated journal · newest first, never edited

2026-08-02 Accumulation · changed $1.52 +0.7% Entry 4

The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.7% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 47%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-07-18 Markup $1.51 +0.0% Entry 3

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D. Technically it is sitting below its long-term trend line with momentum reading overbought. Over the past year the shares are down 47%. Our forward projection puts the odds of a 10% gain over the next month near 27%.

2026-07-03 Markup $1.51 +0.0% Entry 2

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved down 0.0% since our last review. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

2026-07-02 Markup $1.51 Entry 1

The framework reads markup. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Ethical screening: PASS with passing ethical screen (70). The risk-adjusted return profile shows modest positive risk-adjusted returns.

Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.

The political ledger · congressional disclosures

Disclosures naming INM
DatePoliticianPartyTypeAmount
6 May2026 Ro Khanna Democrat sell 1K–15K
27 Mar2026 Alan Armstrong Republican buy 1K–15K
21 Jul2026 April McClain Delaney Democrat sell 1K–15K
2026-04-21 Ro Khanna Democrat Sale 1K–15K
2026-04-20 Ro Khanna Democrat Sale 15K–50K

What holding actually paid · price plus dividends

If $1,000 had been placed · historical, not a promise
PeriodPrice thenPrice returnDivs per share$1,000 becameTotal return
1 month $0.62 +135.1% · $2,351 +135.1%
2 months $0.72 +103.9% · $2,039 +103.9%
3 months $0.80 +82.5% · $1,825 +82.5%
6 months $1.39 +5.0% · $1,050 +5.0%
1 year $2.77 -47.3% · $527 -47.3%
2 years $4.94 -70.5% · $296 -70.5%
3 years $26.00 -94.4% · $56 -94.4%
5 years $1,420.00 -99.9% · $1 -99.9%

Historical returns from market close data. Past performance does not guarantee future results.

This entry now belongs to the ledger. Whatever INM does next, these words stay.

InMed Pharmaceuticals Inc · INM · Markdown · $1.52
Recorded 2025-06-30 · before the outcome · scored mechanically

Get our weekly market brief free.